Adaptive Biotechnologies Expects MRD Business Revenue Between $255 Million and $265 Million
The company said, "Adaptive Biotechnologies expects full year revenue for the MRD business to be between $255 million and $265 million. No revenue guidance is provided for the Immune Medicine business. We expect full year total company operating expenses, including cost of revenue, to be between $350 million and $360 million."
